Predicting if a person's HIV will resist antibody treatments to personalize care
Predicting HIV-1 escape from therapeutics in vitro and in vivo - toward personalizing medicine for people living with HIV
This project aims to use each person's HIV genetic information and lab tests to forecast how likely the virus is to become resistant to specific antibody treatments for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11308271 on NIH RePORTER |
What this research studies
Researchers will collect virus samples from patients' blood and the hidden reservoir and read the viral genetic code to find features linked to resistance. They will test viral proteins in the lab and use computer models to predict how likely the virus is to escape different broadly neutralizing antibody treatments. Lab results (in vitro) will be compared with what happens in patients (in vivo) to refine those predictions. The goal is to develop tools clinicians could use to pick antibody therapies that are less likely to fail for each person.
Who could benefit from this research
Good fit: People living with HIV who can provide blood samples and who are considering or receiving antibody-based therapies (or who have detectable virus) would be the best fit for this work.
Not a fit: People who are stably suppressed on standard antiretroviral therapy and are not candidates for antibody treatments, or those unable to provide samples, are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this could help doctors choose antibody treatments that are less likely to stop working for an individual, lowering the chance of treatment failure.
How similar studies have performed: Broadly neutralizing antibody trials have shown promise but viral escape is common, and using viral sequence features to reliably predict escape is a newer, still-developing approach.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Haim, Hillel — University of Iowa
- Study coordinator: Haim, Hillel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.